EUCTR2009-014997-16-AT
Active, not recruiting
Phase 1
Identification of patients with high probability of not or poorly responding to therapy with mycophenolic acid pro-drugs.
Medizinische Universität Wien, Abteilung für Nephrologie und Dialyse0 sites150 target enrollmentOctober 21, 2009
ConditionsPatients with a de novo kidney transplantationMedDRA version: 12.0Level: LLTClassification code 10023438Term: Kidney transplant
DrugsMyfortic
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Patients with a de novo kidney transplantation
- Sponsor
- Medizinische Universität Wien, Abteilung für Nephrologie und Dialyse
- Enrollment
- 150
- Status
- Active, not recruiting
- Last Updated
- 5 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •de novo kidney graft
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1\.2 Adults (18\-64 years) yes
- •F.1\.2\.1 Number of subjects for this age range
- •F.1\.3 Elderly (\>\=65 years) yes
- •F.1\.3\.1 Number of subjects for this age range
Exclusion Criteria
- •highly immunized patients (due to previous transplantations etc) with PRA levels \>40%
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Early identification of patients who benefit from palbociclib in addition to letrozoleMetastatic breast cancer10027476NL-OMON46198niversitair Medisch Centrum Groningen30
Active, not recruiting
Phase 1
Early identification of patients who benefit from palbociclib in addition to letrozoleEUCTR2015-004231-12-NLniversity Medical Center Groningen
Completed
Not Applicable
TOPSbreast cancerJPRN-UMIN000037067Osaka International Cancer Institute200
Unknown
Not Applicable
Decision tool topklinische GGZ voor ouderen met een persoonlijkheidsstoornis: Ontwikkeling en validering.Personality disorder, older adultsNL-OMON20506Mondriaan Hospital, Department of Old Age Psychiatry.90
Completed
Not Applicable
Study on the selection of appropriate patients for the dose escalation of adalimumab in Crohn's disease therapy.Crohn'diseaseJPRN-UMIN000024566Toho University Medical Center Sakura Hospital60